MYHEALTHCHECKED PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10 GBX | 0.00% |
|
0.00% | -24.53% |
| 01-11 | MyHealthChecked expects 2023 earnings breakeven | AN |
| 01-11 | MyHealthChecked PLC Provides Revenue Guidance for the Full Year 2023 | CI |
| Sales 2021 | 16.38M 20.55M 1.64B | Sales 2022 | 22.31M 28M 2.23B | Capitalization | 12.29M 15.42M 1.23B |
|---|---|---|---|---|---|
| Net income 2021 | 2M 2.51M 200M | Net income 2022 | 1M 1.25M 100M | EV / Sales 2021 | 0.69 x |
| Net cash position 2021 | 6.39M 8.01M 639M | Net cash position 2022 | 7.56M 9.48M 756M | EV / Sales 2022 | 0.21 x |
| P/E ratio 2021 |
8.7
x | P/E ratio 2022 |
8.29
x | Employees | 21 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.38% |
More Fundamentals
* Assessed data
More news
| 1 month | -13.04% | ||
| 3 months | -11.11% | ||
| 6 months | -6.98% | ||
| Current year | -24.53% |
1 week
9.50
10.50
1 month
9.5012.00
Current year
9.5016.00
1 year
8.2629.99
3 years
8.2685.35
5 years
8.26111.72
10 years
8.26340.05
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 13/11/19 | |
Bhavika Patel
CTO | Chief Tech/Sci/R&D Officer | 37 | - |
| Director/Board Member | 66 | 10/04/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Adam Reynolds
CHM | Chairman | 59 | 16/02/16 |
Lyn Rees
BRD | Director/Board Member | 51 | 13/11/19 |
| Director/Board Member | 58 | 27/03/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 10 | 0.00% | 0 |
| 02/05/24 | 10 | 0.00% | 10,000 |
| 01/05/24 | 10 | 0.00% | 5,128 |
| 30/04/24 | 10 | +2.56% | 76,907 |
| 29/04/24 | 9.75 | -2.50% | 91,724 |
Delayed Quote London S.E., May 03, 2024 at 04:35 pm
More quotes
MyHealthChecked PLC is a United Kingdom-based consumer home-testing healthcare company. The Company is the umbrella brand of a range of at-home rapid tests, as well as deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and blood sample collection kits. The Company also provides COVID tests. The Company's multi-platform portfolio of tests offers users access to a variety of test types, sample collection options, and levels of analysis, enabling it to meet diverse customer needs. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analyzed in partner laboratories for a range of biomarkers. The tests have been made available online and for over-the-counter purchase. All its business activity is underpinned by two distinct routes to market: business to business to consumer (B2B2C) and direct to consumer.
Calendar
30/05/2024
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.53% | 6.53M | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| -1.33% | 62.38B | |
| +11.80% | 51.37B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B | |
| +26.14% | 31.88B |
- Stock Market
- Equities
- FRI Stock
